semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Ventilator Associated Pneumonia Infection Trauma adults >18 and < 80 years oldmultitrauma patients with at least two organ-system injury intubated immediately after injury likelihood that the patient would require mechanical ventilation with an endotracheal tube (or tracheostomy) for >10 days life expectancy > 15 days  investigators unable to obtain informed written consent from patients' relatives administer the first dose of the study drug within 24 hours of intubation pregnancy; lactation; immunosuppression; hematologic disease; prosthetic cardiac valve or vascular graft; cardiac trauma; history of rheumatic fever, endocarditis, or congenital cardiac abnormality; oropharyngeal mucosal injury; recent history of sinusitis and respiratory tract infection obesity [BMI > 40] administration of antibiotics for > 3 days before recruitment into the study administration of probiotics before recruitment into the study history of infection from Hepatis B or C and HIV administration of < 90% of the predicted doses of probiotics during the study period
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  Gynecologic Cancer Chemotherapy Gynecologic cancer patients under chemotherapy aged 20 and above  Patients who had been enrolled for other investigational drug trials within the data collection period of this study
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Peritoneal Adhesion Pathologically and radiologically confirmed stage IV or postoperative recurrence ovarian cancer. 2. Age of 18-70, Karnofsky score higher than 80. 3. No severe functional damage of major organ, normal liver and kidney function. 4. Peritoneal adhesion. (1) peritoneal adhesions diagnosed by microlaparoscopy or abdominal operations, and classification according to Nair is performed. (1) must be met. (2) Peritoneal adhesion symptoms, intermittent abdominal pain, abdominal distension, nausea and vomiting, hard to pass stools or gas; (3) Peritoneal adhesion signs，abdominal distension, abdominal tenderness, reduced or absent bowel sounds; (4) B ultrasound or CT or MRI show peritoneal adhesion or adhesion-related complications  Complete intestinal obstruction and suitable for surgery. 2. Patients known to be allergic to bevacizumab or any of the components of the drug. 3. Other ongoing anti-tumor treatment. 4. Heart disease with significant clinical symptoms, such as: congestive heart failure, coronary heart disease with symptom, arrhythmia hardly be controlled by drugs, myocardial infarction in 6 months, or heart failure 5. Active wound infection and a history of uncontrolled psychiatric illness. -
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Gastrointestinal Disorder, Functional   Visual impairment Inability to read Inability to understand English Inability to use a computer to respond to questions
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 1.0-99.0,  Clostridium Difficile As subjects must meet standard clinical for candidacy for FMT, all patients will have suffered symptomatic diarrhea and have documented stool c. difficile toxin positivity. Almost all patients will have failed standard therapy for CDI, which includes at least one course of treatment with a primary agent (metronidazole, vancomycin or fidaxomicin), as well as an extended vancomycin taper following either the second or third recurrence. There may be extenuating circumstances that could justify FMT for CDI outside of these parameters, such as severe allergy to multiple of the above agents, though this would be expected to be exceedingly rare. 2. All patients must be able to tolerate either colonoscopy (including anesthesia and sedation) or placement of a nasogastric/nasoduodenal tube, without a contraindication to the procedure  Pregnancy 2. Prisoners (for concerns of vulnerability and logistics) 3. Adult patients who are themselves unconsentable at time of FMT. 4. Life expectancy judged to be <3 months 5. Need for extended antibiotics at baseline, for an indication other than treatment for CDI 6. Any patient who the clinician judges to be a poor candidate for FMT, for reasons of comorbidities or not being able to tolerate the procedure for administration, would by definition be excluded from the study
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Chronic Constipation Diabete Mellitus Type II diabetics Functional Constipation defined by Rome III are as follows: a. At least a 6 months history of constipation. b. Less than three spontaneous bowel movements (SBMs) per week. c. At least 25% of stools are lumpy or hard stools as it is described in Bristol Stool Form Scale (BSFS) less than score of 6. d. Sensation of incomplete evacuation following at least 25% of bowel movements. e. Straining on at least 25% of defecations. f. Sensation of anorectal obstruction/blockage for at least 25% of defecations. Note: The above are only applicable to spontaneous bowel movements. Patients who have no spontaneous bowel movements (bowel movements are preceded by laxative intake) are considered constipated and are eligible for this study For patients' ≥ 50 years of age, normal colonic anatomy as documented by colonoscopy or double-contrast barium enema, performed within the previous 5 years, based on the American Gastroenterological Association guidelines Patients with confirm diagnosis of Diabetic Autonomic Neuropathy based on results of ANX 3.0, real-time ANS monitoring system will be included in this investigation Patients diagnosed with diabetic peripheral neuropathy and/or symptoms of functional gastroduodenal disorders, such as GERD and functional dyspepsia may participate in a study  Pregnancy or lactation Subjects unwilling to practice adequate contraception throughout the period of screening through 14 days after study termination Loose or watery stools reported in the absence of laxatives for >25% of BMs during the screening period by using Bristol Stool Form Scale (BSFS) Use of laxatives 3 days immediately prior to randomization (except fiber or bulking agents) and chronic laxative use during the trial Patients diagnosed with severe, drug refractory gastroparesis (persistent daily vomiting), currently receiving parenteral feeding (N-G, J-G-Tubes), having history of frequent hospitalizations, or being implanted with gastric neurostimulation system Use of any of the following drugs within 3 days prior randomization and during the trial: a. Prokinetic agents (domperidone, metoclopramide, erythromycin). b. Medication containing opiates. c. Anti-spasmodic (e.g. Atropine, hyoscamine, scopolamine, glycopyrrolate) Hemoglobin A1c>8.2 Use of illegal drugs Regular consumption of more than 2 drinks of alcohol per day Chronic, more than 3/week use of NSAIDs
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Irritable Bowel Syndrome Fecal Microbiota Transplantation Patients are aged 18 or above Patients have a diagnosis of IBS consistent with the Rome III (13) Patients did not have adequate relief of global IBS symptoms and of IBS-related bloating at both the time of screening and the time of randomization Patients had undergone clinical investigations with colonoscopy within two years of recruitment Patients with written informed consent form provided  Patients have constipation predominant IBS (according to the definition of Rome III criteria) Patients have a history of inflammatory bowel disease or gastrointestinal malignancy Patients have previous abdominal surgery (other than cholecystectomy or appendectomy) Patients have human immunodeficiency virus infection Patients have renal disease manifested by 1.5 times the ULN of serum creatinine or blood urea nitrogen level Patients have hepatic disease manifested by twice the upper limit of normal (ULN) for any of the following liver function tests: alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, or total bilirubin (except in isolated elevation of unconjugated bilirubin Patients have diabetes mellitus manifested by HbA1C > 6.5% Patients have abnormal thyroid function manifested by values of serum Sensitive Thyroid Stimulating Hormone and serum free T4 fall outside the reference range which is not controlled by thyroid medications Patients have a history of psychiatric illness (mania and schizophrenia) Patients have depression defined by having a Patient Health Questionnaire-9 (PHQ-9) score > 15
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Urinary Tract Infections Non-pregnant, nonlactating woman with moderate to severe symptoms of urinary tract infection On adequate birth control Normal ECG  Participated in any other trial within 30 days of visit 1 Known or suspected allergy to investigational drug Narrow angle glaucoma Recovering from chicken pox or flu-like symptoms History of peptic ulcer, gastrointestinal bleeding, gastrointestinal surgery, or gastrointestinal dysfunction which could interfere with drug absorption Taken any drugs for within past 24 hours for symptoms associated with uncomplicated urinary tract infections Currently taking prohibited drugs Taken an antibiotic within 7 days of Visit 1 Are ineligible to receive an antibiotic History of urinary retention
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Clostridium Difficile Infection Clostridium Difficile Diarrhea Index episode of CDI based on the presence of diarrhea (defined as ≥3 unformed bowel movements/24h) plus an enzyme immunoassay (EIA) detecting Glutamate dehydrogenase (GDH) or polymerase chain reaction (PCR) for toxin B test plus a positive EIA for toxin A and B Ongoing or new hospitalization at into the study Written informed consent (IC) has been obtained from the study subject or a legal representative  Patient with any social or logistical condition which in the opinion of the investigator may interfere with the conduct of the study, such as incapacity to well understand, not willing to collaborate, or cannot easily be contacted after discharge CDI episode within the previous 84 days
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 4.0-999.0,  Inflammatory Bowel Diseases Irritable Bowel Syndrome Ulcerative Colitis Crohn Disease Indeterminate Colitis Chronic Diarrhea Celiac Disease Diverticulitis Abdominal Pain Distension Weight Loss Food Intolerance Constipation Subject is of either gender and ≥ 4 years of age Subject is showing signs and symptoms of IBD and/or IBS Diagnosis of IBD, IBS or other gastrointestinal disorder is performed by colonoscopy Subject or authorized legal representative is willing and able to sign the IRB approved Informed Consent form or able to provide Informed Consent in accordance with 21 CFR 50 CFR 50 Subpart B Subject is able to understand and follow study sample collection procedure  Subject has undergone a surgical resection or diversion procedure Subject is currently taking (non-steroidal anti-inflammatory drugs, i.e. ibuprofen, Advil, Motrin, Naproxen, Aleve including regular dose and low dose aspirin) within 7 days of colonoscopy and sample collection Subject who has taken immunomodulators or biologic therapies within the previous 6 months of colonoscopy and sample collection Subject who is currently pregnant or lactating Subject is unable or unwilling to follow informed consent Inability or unwilling to perform required study procedures
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 40.0-90.0,  Stroke, Ischemic Intensive Care Neurological Disorder Morality Rehabilitation acute ischemic stroke confirmed by computed tomography or a diffusion-weighed magnetic resonance imaging scan aged > 40 years ability to understand and follow simple verbal instructions modified Rankin scale score > 2 National Institute of Health Stroke Scale score > 0 no unrestricted movement of the lips no receptive aphasia and no history of thoracic or abdominal surgery  blood pressure >180/100 mm Hg more than twice in 24 h significant pulmonary disease, angina, myocardial infarction or acute heart failure within three months neurological conditions other than stroke presence of a severe visual disability and visual field defects receiving medications that would influence the metabolic or cardiorespiratory responses to exercise inability to perform the tests
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 60.0-120.0,  Osteo Arthritis Knee Criteria:• Patients undergoing primary TKR at the RD+E Hospital Patients must have completed a consent form for the study Patients must be prepared to comply with the pre and post-operative investigations, rehabilitation, attendance schedule and questionnaire schedule of the study Patient in whom any varus deformity present is <20° The diagnosis is of tricompartmental osteoarthritis of the knee Patient has primary diagnosis of Non-Inflammatory Degenerative Joint Disease (NIDJD) BMI<40 Aged =/> 60 years at time of surgery  • Refusal to consent to the study If the knee for surgery has a fixed flexion deformity ≥15° this will be assessed by a lateral "heel-hang" x-ray of the knee for surgery If the knee for surgery has a varus deformity ≥20° If the knee for surgery has a valgus deformity i.e. hip/knee/ankle alignment angle <0° Pre-op Oxford Knee Score <8 Pre-op knee flexion ability <90° If the natural posterior tibial slope measured is in excess of 10° Any patient whose post-operative recovery or ability to comply with the post-operative rehabilitation and assessment schedules is compromised by known existing other medical conditions Pregnancy
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Clostridium Difficile Infection Age 18 years and older Any history of Clostridium difficile infection based on a positive Clostridium difficile stool test performed at a lab affiliated with Rochester Regional Health System or patient report A new in-patient admission, with an antibiotic treatment plan for greater than 48 hours  Documented allergy and/or adverse drug reaction to vancomycin Pregnant Patients who are admitted with a current episode of Clostridium difficile infection Patients with total colectomy
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Thrombotic Microangiopathies Patients be scheduled to undergo HSCT; 2. Not received decitabine 6 month ago; 3. Without severe organ damage; 4. ECOG 0-2; 5. Informed consent were obtained  Be sensitive to NAC; 2. Bronchial asthma； 3. Peptic ulcer； 4. Severe organ damage； 5. Pregnancy and breastfeeding women；
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Sepsis A primary diagnosis of sepsis or septic shock (the diagnoses of sepsis and septic shock are based on the 2016 the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)) and a procalcitonin (PCT) level≥2ng/mL. Sepsis: Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. Septic shock: Septic shock is a subset of sepsis in which underlying circulatory and cellular/metabolic abnormalities are profound enough to substantially increase mortality  Patients < 18 years of age, pregnant patients, and patients with limitations of care